Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429050 | 0.86 | MAP2K1 (0.47) | MAP2K1GRIK1MEN1KMT2AFTO | |
| SCHEMBL13841944 | 0.86 | MEN1 (0.60) | MAP2K1HTTMEN1KMT2ATAS2R14 | |
| SCHEMBL1341502 | 0.85 | KDM4E (0.47) | KDM4EMAP2K1MAP2K2HTTMEN1 | |
| SCHEMBL4860207 | 0.82 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL16571766 | 0.79 | MAP2K1 (0.65) | KDM4EMAP2K1MAP2K2HTTGRIK1 | |
| SCHEMBL29908900 | 0.79 | MAP2K1 (0.65) | KDM4EMAP2K1MAP2K2HTTGRIK1 | |
| SCHEMBL23694495 | 0.78 | MAP2K1 (0.45) | MAP2K1MAP2K2 | |
| SCHEMBL15129529 | 0.78 | KDM4E (0.50) | KDM4EMAP2K1MAP2K2HTTGRIK1 | |
| SCHEMBL4854933 | 0.76 | MAP2K1 (0.62) | MAP2K1MAP2K2 | |
| SCHEMBL15129689 | 0.76 | KDM4E (0.48) | KDM4EMAP2K1MAP2K2HTTGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2121620-A1 | INHIBITORS OF MEK | Ardea Biosciences, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008089459-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1689233-A4 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | MAPK8, MAP3K8, MAP3K2 | KDM4E 1231/4885MAP2K1 51/4885MAP2K2 38/4885 |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, MAPK1, BDKRB1 | KDM4E 1815/4885MAP2K1 393/4885MAP2K2 233/4885 |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 960/4885MAP2K1 33/4885MAP2K2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.